Loading...
A Randomized Trial of Empagliflozin to Increase Plasma Sodium Levels in Patients with the Syndrome of Inappropriate Antidiuresis
BACKGROUND: Treatment options to address the hyponatremia induced by the syndrome of inappropriate antidiuresis (SIAD) are inadequate. The sodium glucose cotransporter 2 (SGLT2) inhibitor empagliflozin promotes osmotic diuresis via urinary glucose excretion and therefore, might offer a novel treatme...
Na minha lista:
| Udgivet i: | J Am Soc Nephrol |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Society of Nephrology
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7062212/ https://ncbi.nlm.nih.gov/pubmed/32019783 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2019090944 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|